← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Aug 30, 2026

Legend Biotech Corp (LEGN)

Healthcare • NASDAQ

$19.88

Legend Biotech Corporation is a Chinese-American biopharmaceutical company headquartered in Somerset, New Jersey, and Shanghai, China, that develops novel cell therapies for oncology and other indications. The company co-developed Carvykti (ciltacabtagene autoleucel, or cilta-cel) with Johnson & Johnson's Janssen, a CAR-T cell therapy for relapsed or refractory multiple myeloma, which represents a potentially transformative treatment for this blood cancer.

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

33.0/100

WEAK BUSINESS

Legend Biotech Corp (LEGN) scores 33/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full LEGN quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full LEGN valuation analysis · → View full LEGN Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-29.6%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)

Operating Margin (Operational Efficiency):CRITICAL (0.0%)

Return on Capital (Capital Efficiency):CRITICAL (-102.2%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

Legend Biotech Corp (LEGN) stock report — Zyberno Score 33/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:19.88

Market Cap:$7.35B

Valuation Multiples (3)

P/B Ratio:7.34x

P/S Ratio:4.34x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$6.45B

Price Action & Momentum (3)

12-1 Momentum:

-43.1% (23th pctile)

📈 Click to view full LEGN Momentum analysis →

Momentum Percentile:23 / 100

% of 52-Week High:53.0%

B. Profitability Assessment

Return Metrics (5)

ROE:

-29.6%

📊 Click to view full LEGN ROE analysis →

ROA:-17.1%

Roic:

-102.2%

📊 Click to view full LEGN ROIC analysis →

Reinvestment Rate:-27.9%

Fundamental Growth Rate (g):28.5%

Margin Analysis (2)

Net Margin Ttm:-17.5%

Ebitda Margin:-8.0%

TTM Performance (2)

Gross Margin Ttm:76.6%

Net Margin Ttm:-17.5%

Yield Metrics (2)

Earnings Yield:-$4.07

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):100.0%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.96x

Quick Ratio:1.91x

Cash Ratio:1.42x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x

Debt-to-Equity Ratio:0.00x

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-6.38x

Times Interest Earned:-6.38

Capital Structure (4)

Working Capital:610,700,000.00

Cash And Cash Equivalents:901,900,000.00

Long Term Debt:$0.00

Net Debt:-$901.90M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $1.70B

Linear Growth: 100.0%

📊 Click to view full LEGN Revenue analysis & methodology →

Cost Of Revenue Ttm:$397.10M

Profitability Breakdown (2)

Gross profit TTM: $1.30B

Linear Growth: 100.0%

📊 Click to view full LEGN Gross Profit analysis & methodology →

-$136.50M

Bottom Line Performance (3)

-$296.80M

Income Before Tax:$0.00

Ebitda Ttm:-136,500,000.00

Operating Expenses (5)

Operating Expenses:0.00

R And D Expense:0.00

Sga Expense:0.00

Income Tax Expense:$14.20M

Interest Expense:21,400,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%

Sga To Revenue Percentage:0.0%

Ebitda Margin:-8.0%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.73B

Current Assets:$1.25B

Ppe Net:116,300,000.00

Goodwill:0.00

Intangible Assets:$1.90M

Liability Structure (4)

Total Liabilities:731,600,000.00

Current Liabilities:636,400,000.00

Long Term Debt:$0.00

Short Term Debt:$0.00

Equity & Capital (3)

Equity:$1.00B

Retained Earnings:$0.00

Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00

Inventory:32,000,000.00

Accounts Payable:0.00

Special Items (2)

Contract Liabilities:0.00

Stock Based Compensation:0.00

C. Cash Flow Analysis

Operating Activities (2)

-$100.20M-$128.80M

Investment Activities (1)

Investing Cash Flow:$256.64M

Financing Activities (3)

Financing Cash Flow:$667.00K

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.81

-$0.81

Earnings Per Share Ttm:-$0.80

Revenue & Cash Per Share (2)

Sales Per Share Ttm:4.59

Operating Cash Flow Per Share:-$0.27

Book Value & Capital (2)

Book Value Per Share:$2.71

Cash Per Share:2.44

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.98x

Working Capital Turnover Ttm:2.78x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x

Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:12.41x

Days Inventory Outstanding Ttm:29.41

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00

Cash Conversion Cycle:29.41

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00

Quality Score:40.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-27.9%

Fundamental Growth Rate (g):28.5%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):100.0%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):100.0%

C. Company Profile & Context

Corporate Information (6)

Symbol:LEGN

Company Name:Legend Biotech Corp

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:medium

Volume Category:N/A

Share Structure (3)

Shares Outstanding:369.89M

Shares Outstanding Basic:0

Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-08-30 00:41:49 UTC

Data Timestamp:2026-08-30T00:41:49.825083